866-997-4948(US-Canada Toll Free)

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 35 Pages

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Pipeline Review, H2 2017

Summary

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report C-C Chemokine Receptor Type 1-Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-C-C chemokine receptor type 1 is a protein encoded by the CCR1 gene. CCR1 binds to multiple chemokines (including CCL4, CCL5, CCL6, CCL14, CCL15, CCL16 and CCL23). This receptor is found on peripheral blood lymphocytes and monocytes. This chemokine receptor is restricted to memory T-cells within the lymphocyte pool. This receptor is also designated cluster of differentiation marker CD191. The molecules developed by companies in Phase II and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Immunology, Oncology and Infectious Disease which include indications Rheumatoid Arthritis, Autoimmune Disorders, Blood Cancer, Bone Metastasis, Breast Cancer, Lupus Nephritis and Systemic Candidiasis.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)
- The report reviews C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Overview
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
ChemoCentryx Inc
Ligand Pharmaceuticals Inc
Novartis AG
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Drug Profiles
BL-5923-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-457-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-354-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-9588-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CCR1 for Oncology-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CCR1 for Oncology-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Dormant Products
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Discontinued Products
C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)-Product Development Milestones
Featured News & Press Releases
Apr 18, 2016: ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Nov 04, 2015: ChemoCentryx presents CCX-9588 preclinical results at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
Jun 08, 2012: ChemoCentryx Announces Peer-Reviewed Publication Of Positive Phase II Clinical Data With CCX354 In Patients With Rheumatoid Arthritis
Nov 08, 2011: ChemoCentryx Reports Clinical Efficacy For CCX354 In Phase II Study In Patients With Rheumatoid Arthritis
Nov 09, 2010: ChemoCentryx Reports Favorable Phase I Results For CCX354 In Rheumatoid Arthritis At Annual American College Of Rheumatology Meeting
Jun 17, 2010: ChemoCentryx Reports Positive Phase I Study Results For CCX354
Dec 16, 2009: ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis
May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Bristol-Myers Squibb Co, H2 2017
Pipeline by ChemoCentryx Inc, H2 2017
Pipeline by Ligand Pharmaceuticals Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *